Article
Immunogenicity of a New Enhanced Tetanus-reduced Dose Diphtheria-acellular Pertussis (Tdap) Vaccine Against Bordetella Pertussis in a Murine Model
2020-12-16
Abstract excerpt
<h4>Background: </h4> The necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2a345dc6-df47-5dd0-9e7e-c6f79875f9ad
- DOI
- 10.21203/rs.3.rs-127484/v1
